Advertisement
Advertisement

HALO

HALO logo

Halozyme Therapeutics, Inc.

67.28
USD
Sponsored
-0.42
-0.63%
Dec 31, 16:00 UTC -5
Closed
exchange

After-Market

67.03

-0.25
-0.37%

HALO Earnings Reports

Positive Surprise Ratio

HALO beat 30 of 40 last estimates.

75%

Next Report

Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q-- -1 (Revenue/ EPS)
--
/
--

Halozyme Therapeutics, Inc. earnings per share and revenue

On Nov 03, 2025, HALO reported earnings of 1.72 USD per share (EPS) for Q3 25, beating the estimate of 1.66 USD, resulting in a 3.56% surprise. Revenue reached 354.26 million, compared to an expected 346.72 million, with a 2.18% difference. The market reacted with a +2.79% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Holdings Inc. Common Stock
Report Date
Dec 22, 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Surprise
-25.95%
logo
Outlook Therapeutics, Inc. Common Stock
Report Date
Dec 19, 2025 For Q4 25
Estimate
-$0.25
Actual
-$0.19
Surprise
+26.47%
logo
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
For Q3 2025, Halozyme Therapeutics, Inc. reported EPS of $1.72, beating estimates by 3.56%, and revenue of $354.26M, 2.18% above expectations.
The stock price moved up 2.79%, changed from $66.20 before the earnings release to $68.05 the day after.
The next earning report is scheduled for --.
Based on -- analysts, Halozyme Therapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement